



Jagsonpal Pharmaceuticals announces Q1 FY23 results

New Delhi, August 09, 2022: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the financial results for the quarter ended June 30th, 2022.

A detailed presentation on the performance is included as part of this press release.

Particulars	Q1FY23	Q1FY22	Growth %
Revenues	6,059.7	5,405.5	12%
Operating EBITDA	1,062.3	999.7	6%
EBITDA %	17.5%	18.5%	(100 bps)

Commenting on the Company's performance, Mr. Manish Gupta, Managing Director stated "I am excited to take up the mantle to lead Jagsonpal, which I believe has a strong business model, a talented team and a trusted name among the medical fraternity.

Building on the momentum of last year, Jagsonpal has delivered another quarter of strong 15% growth as per IQVIA. The company has improved its ranking in the Indian Pharmaceutical Industry by 9 positions to be the 80th ranked company based on its performance for MAT June'22. The Dydrogesterone franchise (Divatrone and ProRetro) continues to grow rapidly gaining a 4% market share in Q1 and Divatrone features among the 'Top 5' new launches in the last 12 months.

Financially, the company delivered a 12% growth in revenues, which stood at ₹ 60 Crores with an Operating EBITDA of ₹ 10.6 Crores, reflecting a 6% growth, due to post-covid normalization of costs. The quarter saw some exceptional and one-time costs based on certain strategic decisions.

We stay confident of maintaining the growth momentum for the rest of the year even as we initiate work on further growth strategies.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the Company has a proven track record of 40+ years of catering to the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on the Gynecology and Orthopedic segments. Over the years, the Company has successfully built multiple brands that today hold

market-leading position in respective segments. It has created a niche for itself in these value-accretive segments which resulted in mid-teens CAGR in revenues over the last four years reaching ₹ 2,176 Million in FY22. It has an extensive pan-India presence through its strong sales team of 900+ individuals.

Infinity Holdings acquired a majority stake in the company and is a joint promoter of the company. The company is listed on the National Stock Exchange Limited (NSE) and Bombay Stock Exchange Limited (BSE).

For more on the Company please visit. www.jagsonpal.com.

Mr. S.V. Subha Rao
Chief Financial Officer
Contact: svrao@jagsonpal.com; 01146181100

Jagsonpal Pharmaceuticals Limited
CIN: L74899DL1978PLC009181
T-210 J, Shahpur Jat, New Delhi – 110049